Media Articles Related to Eloxatin (Oxaliplatin)
Sanofi launches authorized generic version of Eloxatin® (oxaliplatin injection)
Source: Colorectal Cancer News From Medical News Today [2014.08.14]
Sanofi US has announced that it has launched an authorized generic version of Eloxatin® (oxaliplatin injection) through Winthrop US, the company's generics division.
FDA approves first non-invasive DNA screening test for colorectal cancer
Source: Colorectal Cancer News From Medical News Today [2014.08.13]
The U.S. Food and Drug Administration has approved Cologuard, the first stool-based colorectal screening test that detects the presence of red blood cells and DNA mutations that may indicate the...
New Colorectal Cancer Screening Test Approved
Source: MedicineNet Cancer Specialty [2014.08.13]
Title: New Colorectal Cancer Screening Test Approved
Category: Health News
Created: 8/12/2014 12:35:00 PM
Last Editorial Review: 8/13/2014 12:00:00 AM
Flexible sigmoidoscopy screening reduces colorectal cancer incidence and rate of death
Source: Colorectal Cancer News From Medical News Today [2014.08.12]
Among about 100,000 study participants, screening with flexible sigmoidoscopy resulted in a reduced incidence and rate of death of colorectal cancer, compared to no screening, according to a study...
Low uptake of colorectal cancer screening by African Americans revealed in a Veterans Affairs healthcare network
Source: Colorectal Cancer News From Medical News Today [2014.08.08]
According to researchers in California, African Americans' participation in colorectal cancer screening is low and the use of colonoscopy infrequent despite similar access to care across races in a...
Published Studies Related to Eloxatin (Oxaliplatin)
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. [2011.07.10]
PURPOSE: To investigate oxaliplatin combined with fluorouracil-based chemoradiotherapy as preoperative treatment for locally advanced rectal cancer... CONCLUSION: Adding oxaliplatin to fluorouracil-based preoperative chemoradiotherapy significantly increases toxicity without affecting primary tumor response. Longer follow-up is needed to assess the impact on efficacy end points.
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. [2011.07]
BACKGROUND: When cure is impossible, cancer treatment should focus on both length and quality of life. Maximisation of time without toxic effects could be one effective strategy to achieve both of these goals. The COIN trial assessed preplanned treatment holidays in advanced colorectal cancer to achieve this aim... INTERPRETATION: Although this trial did not show non-inferiority of intermittent compared with continuous chemotherapy for advanced colorectal cancer in terms of overall survival, chemotherapy-free intervals remain a treatment option for some patients with advanced colorectal cancer, offering reduced time on chemotherapy, reduced cumulative toxic effects, and improved quality of life. Subgroup analyses suggest that patients with normal baseline platelet counts could gain the benefits of intermittent chemotherapy without detriment in survival, whereas those with raised baseline platelet counts have impaired survival and quality of life with intermittent chemotherapy and should not receive a treatment break. FUNDING: Cancer Research UK. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. [2011.06.18]
BACKGROUND: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (EGFR)-targeted antibody cetuximab was added to standard chemotherapy in first-line treatment of advanced colorectal cancer with the aim of assessing effect on overall survival... INTERPRETATION: This trial has not confirmed a benefit of addition of cetuximab to oxaliplatin-based chemotherapy in first-line treatment of patients with advanced colorectal cancer. Cetuximab increases response rate, with no evidence of benefit in progression-free or overall survival in KRAS wild-type patients or even in patients selected by additional mutational analysis of their tumours. The use of cetuximab in combination with oxaliplatin and capecitabine in first-line chemotherapy in patients with widespread metastases cannot be recommended. FUNDING: Cancer Research UK, Cancer Research Wales, UK Medical Research Council, Merck KGgA. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma. [2011.06]
BACKGROUND: To investigate the efficacy and toxicity of FOLFOX4 regimen and LV5Fu2 regimen in patients with advanced gastric adenocarcinoma after curative gastrectomy... CONCLUSION: FOLFOX4 regimen showed good efficacy and an acceptable safety profile for patients with advanced gastric adenocarcinoma after curative gastrectomy compared with the control group. It may prove to be a suitable alterative regimen in this indication. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. [2011.05.20]
PURPOSE: PTK787/ZK 222584 (PTK/ZK; vatalanib), an orally active, multitargeted angiogenesis inhibitor, has shown tolerability and promising activity in early-phase studies, which led to a phase III trial in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4)... CONCLUSION: Although the efficacy objectives of this study were not met, a subgroup of patients who may potentially benefit from small-molecule vascular endothelial growth factor receptor inhibitor therapy has been identified and further research is warranted.
Clinical Trials Related to Eloxatin (Oxaliplatin)
XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer [Active, not recruiting]
XELOX (Capecitabine and Oxaliplatin) is an effective and convenient regimen for patients with
metastatic colorectal cancer. Chronomodulated therapy may reduce toxicity. Patients will be
randomized to standard XELOX (Capecitabine 1000 mg/m˛ in the morning and 1000 mg/m˛ in the
evening days 1-14 and short term Oxaliplatin 130 mg/m˛ day 1 in 30 minutes) or
chronomodulated XELOX (Capecitabine 400 mg/m˛ in the morning and 1600 mg/m˛ in the evening
days 1-14 and short term Oxaliplatin 130 mg/m˛ day 1 in 30 minutes).
Bloodsamples will be collected and frozen and later examined for potential predictive
Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer [Recruiting]
The aim of this study is to compare the activity and safety of Oxaliplatin and S-1 (OS) and
Oxaliplatin and Capecitabine (XELOX) in patients with advance or recurrent colorectal
Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer [Recruiting]
This study is to test escalating doses of intraperitoneal (IP) oxaliplatin in conjunction
with systemic bevacizumab and capecitabine in patients with Peritoneal Carcinomatosis (PC)
from either appendiceal or colorectal adenocarcinoma that have been adequately cytoreduced
and have undergone a peritoneal scan demonstrating patency of at least one of the
intraperitoneal ports that were placed at the time of debulking.
Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer [Recruiting]
Primary objective :
To compare the combination of S-1 and oxaliplatin(SOX) to the combination of capecitabine
and oxaliplatin(COX) therapy for advanced or metastatic colorectal carcinoma.
Secondary objectives :
1. To evaluate and compare the efficacy (overall survival and response rate) in the two
2. To evaluate and compare the quality of life of the patients and safety profiles of
the two treatment groups.
XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib [Recruiting]
The primary purpose of this study is to find the highest tolerated dose of the study drugs:
capecitabine, oxaliplatin, bevacizumab, and dasatinib given in combination to subjects with
advanced solid tumors. This will occur in the first part of the study (Phase I). Once this
dose has been determined, it will be given to subjects with advanced metastatic colorectal
cancer in the second part of the study (Phase II).
By giving these drugs in combination, researchers hope to evaluate the side effects of the
study drugs in both groups, and to determine if this combination could possibly decrease or
stabilize the cancer being treated.
Subjects will be enrolled at Duke University Medical Center (DUMC) and Rocky Mountain
After satisfying eligibility and screening criteria, patients will be treated on 21 day
ABOUT THE STUDY DRUGS
- Capecitabine (Xelodaâ„˘) is an oral (taken by mouth) chemotherapy drug in tablet form
made by Roche Laboratories Inc. Capecitabine has been approved for use by the Food and
Drug Administration (FDA) for first line treatment (treatment that should be used for
cancer that has not been treated yet) of metastatic colorectal cancer and also for
metastatic breast cancer.
- Oxaliplatin (Eloxatinâ„˘) is an intravenous (given by injection into a vein) chemotherapy
drug made by Sanofi-SynthĂ©labo. This drug is also approved by the FDA for use in
metastatic colorectal cancer.
- Bevacizumab (Avastinâ„˘) is a type of intravenous cancer treatment called anti-angiogenic
therapy (a type of therapy to treat cancer that interferes with blood flow to the
tumor, thereby stopping tumor growth, and possibly leading to tumor shrinkage) made by
Genentech Inc. Bevacizumab is approved by the FDA for first line treatment of
metastatic colorectal cancer in combination with other chemotherapy.
- Dasatinib (Sprycelâ„˘) is an oral drug made by BMS, Inc. Dasatinib is approved by the
FDA for the treatment of chronic myeloid leukemia (CML), acute lymphoblastic leukemia
or for patients that are resistant to a medicine called imatinib mesylate (Gleevecâ„˘ ).
Reports of Suspected Eloxatin (Oxaliplatin) Side Effects
Abdominal Pain (18),
Renal Failure Acute (12),
Asthenia (12), more >>